Related Experiment Videos
Endostatin action and intracellular signaling: beta-catenin as a potential target?
Johan Dixelius1, Michael J Cross, Taro Matsumoto
1Department of Genetics and Pathology, Rudbeck Laboratory, Dag Hammarskjölds v. 20, 751 85 Uppsala, Sweden.
Abstract:
Endostatin, the C-terminal part of collagen XVIII, has been shown to inhibit blood vessel formation in different pathological conditions characterized by increased angiogenesis, such as growing tumors. Subcutaneous injection of endostatin in tumor-bearing mice leads to decreased tumor growth, and even in some cases, cure of tumor disease. Endostatin has been tested in a clinical phase I study and shown not to be toxic. Whether the finding in mice that endostatin treatment does not result in development of resistance will hold true in humans is too early to tell. Endostatin binds to a specific motif in heparan sulfate, which may serve a co-receptor function. The structure of a potential primary receptor is not known. The mechanism of action of endostatin in inhibition of angiogenesis and thereby, inhibition of tumor growth, involves apoptosis of tumor cells. The most consistent effect of endostatin on endothelial cells in vitro is inhibition of endothelial cell migration, which may be due to disturbed cell-matrix interactions. An interesting candidate for transducing endostatin's effect on apoptosis and cell migration is beta-catenin, an intracellular protein which participates both in cell adhesion and in transcriptional regulation.
Insights
Endostatin, derived from collagen XVIII, inhibits tumor growth by preventing new blood vessel formation. Studies show it reduces tumor size and may induce tumor cell death, with no observed toxicity in early human trials.
Area of Science:
- Biochemistry
- Molecular Biology
- Oncology
Background:
- Endostatin, a collagen XVIII fragment, inhibits angiogenesis.
- Angiogenesis is crucial for tumor growth.
- Endostatin has shown efficacy in preclinical tumor models.
Purpose of the Study:
- To investigate the anti-angiogenic and anti-tumor effects of endostatin.
- To explore the mechanism of action of endostatin in tumor suppression.
- To assess the safety and potential of endostatin in clinical settings.
Main Methods:
- Administration of endostatin to tumor-bearing mice.
- In vitro studies on endothelial cell migration and apoptosis.
- Analysis of endostatin's interaction with heparan sulfate and potential receptors.
- Investigation of beta-catenin's role in endostatin's mechanism.
Main Results:
- Subcutaneous endostatin injection decreased tumor growth in mice, with some cures.
- Endostatin demonstrated no toxicity in a phase I clinical study.
- Endostatin inhibits endothelial cell migration in vitro, potentially via disturbed cell-matrix interactions.
- Endostatin induces apoptosis of tumor cells.
Conclusions:
- Endostatin is a promising anti-angiogenic agent for cancer therapy.
- Endostatin's mechanism involves inhibiting endothelial cell migration and inducing tumor cell apoptosis.
- Further research is needed to confirm endostatin's efficacy and resistance profile in humans.